Numerous studies have shown that changes in the expression of IGFBP7 (FSTL2) are also observed in various types of cancer, including HCC, breast cancer, gastrointestinal cancer, prostate cancer, and many others. Here, IGFBP7 is linked to prostate carcinoma.